These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 29155256)

  • 1. Role of toll-like receptors in inflammatory bowel disease.
    Kordjazy N; Haj-Mirzaian A; Haj-Mirzaian A; Rohani MM; Gelfand EW; Rezaei N; Abdolghaffari AH
    Pharmacol Res; 2018 Mar; 129():204-215. PubMed ID: 29155256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like Receptors and Inflammatory Bowel Disease.
    Lu Y; Li X; Liu S; Zhang Y; Zhang D
    Front Immunol; 2018; 9():72. PubMed ID: 29441063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?
    Fernandes P; MacSharry J; Darby T; Fanning A; Shanahan F; Houston A; Brint E
    Clin Exp Immunol; 2016 Mar; 183(3):358-68. PubMed ID: 26462859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptors: promising therapeutic targets for inflammatory diseases.
    Achek A; Yesudhas D; Choi S
    Arch Pharm Res; 2016 Aug; 39(8):1032-49. PubMed ID: 27515048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptors in inflammatory bowel diseases: a decade later.
    Cario E
    Inflamm Bowel Dis; 2010 Sep; 16(9):1583-97. PubMed ID: 20803699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of toll-like receptors in gastrointestinal inflammation.
    Ishihara S; Rumi MA; Ortega-Cava CF; Kazumori H; Kadowaki Y; Ishimura N; Kinoshita Y
    Curr Pharm Des; 2006; 12(32):4215-28. PubMed ID: 17100624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics.
    Gomariz RP; Gutiérrez-Cañas I; Arranz A; Carrión M; Juarranz Y; Leceta J; Martínez C
    Curr Pharm Des; 2010; 16(9):1063-80. PubMed ID: 20030612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes.
    Gooshe M; Abdolghaffari AH; Gambuzza ME; Rezaei N
    Rev Neurosci; 2014; 25(5):713-39. PubMed ID: 24914714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Goldilocks Conundrum: NLR Inflammasome Modulation of Gastrointestinal Inflammation during Inflammatory Bowel Disease.
    Ringel-Scaia VM; McDaniel DK; Allen IC
    Crit Rev Immunol; 2016; 36(4):283-314. PubMed ID: 28322135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases.
    De Jager PL; Franchimont D; Waliszewska A; Bitton A; Cohen A; Langelier D; Belaiche J; Vermeire S; Farwell L; Goris A; Libioulle C; Jani N; Dassopoulos T; Bromfield GP; Dubois B; Cho JH; Brant SR; Duerr RH; Yang H; Rotter JI; Silverberg MS; Steinhart AH; Daly MJ; Podolsky DK; Louis E; Hafler DA; Rioux JD; ;
    Genes Immun; 2007 Jul; 8(5):387-97. PubMed ID: 17538633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineating the Role of Toll-Like Receptors in Inflammatory Bowel Disease.
    Liang H; Zhang L; Hoden B; Qu B; Derubeis D; Song X; Zhang D
    Methods Mol Biol; 2023; 2700():221-228. PubMed ID: 37603184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The innate immune system and inflammatory bowel disease.
    Davies JM; Abreu MT
    Scand J Gastroenterol; 2015 Jan; 50(1):24-33. PubMed ID: 25523553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of chloroquine in a murine model of inflammatory bowel disease.
    Nagar J; Ranade S; Kamath V; Singh S; Karunanithi P; Subramani S; Venkatesh K; Srivastava R; Dudhgaonkar S; Vikramadithyan RK
    Int Immunopharmacol; 2014 Aug; 21(2):328-35. PubMed ID: 24859061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory.
    Levin A; Shibolet O
    World J Gastroenterol; 2008 Sep; 14(33):5149-53. PubMed ID: 18777591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease.
    Zhong W; Kolls JK; Chen H; McAllister F; Oliver PD; Zhang Z
    Front Biosci; 2008 Jan; 13():1654-64. PubMed ID: 17981657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IBD immunopathogenesis: A comprehensive review of inflammatory molecules.
    Park JH; Peyrin-Biroulet L; Eisenhut M; Shin JI
    Autoimmun Rev; 2017 Apr; 16(4):416-426. PubMed ID: 28212924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-Like Receptors as Drug Targets in the Intestinal Epithelium.
    McKernan DP
    Handb Exp Pharmacol; 2022; 276():291-314. PubMed ID: 34783909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Toll-like receptors with small molecule agents.
    Wang X; Smith C; Yin H
    Chem Soc Rev; 2013 Jun; 42(12):4859-66. PubMed ID: 23503527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic impact of toll-like receptors on inflammatory bowel diseases: a multiple-edged sword.
    Cario E
    Inflamm Bowel Dis; 2008 Mar; 14(3):411-21. PubMed ID: 17941072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokines as novel therapeutic targets for inflammatory bowel disease.
    Nishimura M; Kuboi Y; Muramoto K; Kawano T; Imai T
    Ann N Y Acad Sci; 2009 Sep; 1173():350-6. PubMed ID: 19758172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.